Table 2.
Demographics, comorbidities, disease severity and outcomes in patient groups.
| Group 1n = 17 | Group 2n = 18 | Group 3n = 11 |
p Group 1 vs 2 |
p Group 1 vs 3 |
p Group 2 vs 3 |
|
|---|---|---|---|---|---|---|
| Age, years, median (IQR) | 63 (22) | 55.5 (20) | 60 (8) | 0.704 | 0.655 | 0.84 |
| Gender, male, number (%) | 13 (76.5) | 12 (66.7) | 10 (90.9) | 0.521 | 0.619 | 0.139 |
| Patients with ≥ 1 comorbidities, number (%) | 12 (70.6) | 10 (55.6) | 9 (81.8) | 0.489 | 0.668 | 0.149 |
| Comorbidities, number (%) | ||||||
| Hypertension | 5 (29.4) | 6 (33.3) | 5 (45.5) | 0.803 | 0.444 | 0.514 |
| Diabetes mellitus | 2 (11.8) | 3 (16.7) | 3 (27.3) | 0.679 | 0.353 | 0.646 |
| Chronic obstructive pulmonary disease |
1 (5.9) | 1 (5.6) | 0 (0) | 1 | 1 | 1 |
| Asthma | 0 (0) | 3 (16.7) | 0 (0) | 0.229 | – | 0.268 |
| Coronary artery disease | 3 (17.6) | 2 (11.1) | 0 (0) | 0.658 | 0.258 | 0.512 |
| End-stage renal disease | 1 (5.9) | 0 (0) | 0 (0) | 0.486 | 1 | – |
| Clinical classifications, number (%) | ||||||
| Non severe/critical | 1 (5.9) | 4 (22.2) | 4 (36.4) |
0.138 |
0.112 |
0.531 |
| Severe | 6 (35.3) | 2 (11.1) | 2 (18.2) | |||
| Critical | 10 (58.8) | 12 (66.7) | 5 (45.5) | |||
| Coronavirus disease 2019 outcomes | ||||||
| Length of total hospital stay (days), median (IQR) |
23 (17) | 22 (29) | 44 (56) | 0.62 | 0.115 | 0.431 |
| Length of hospital stay after first IVIg dose(days), median (IQR) |
8 (11) | 14.5 (25) | 11 (22) | 0.258 | 0.286 | 0.804 |
| Intubation, number (%) | 11 (64.7) | 12 (66.7) | 5 (45.5) | 0.903 | 0.315 | 0.26 |
| Intensive care unit admission, number (%) |
13 (76.5) | 13 (72.2) | 7 (63.6) | 0.774 | 0.471 | 0.628 |
| Death, number (%) | 11 (64.7) | 9 (50) | 2 (18.2) | 0.38 | 0.016 | 0.087 |
n: number, IQR: interquartile range, IVIg: intravenous immunoglobulins.